These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 18301797)

  • 1. Epigenome-derived drugs: recent advances and future perspectives.
    Vogiatzi P; Aimola P; Scarano MI; Claudio PP
    Drug News Perspect; 2007 Dec; 20(10):627-33. PubMed ID: 18301797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic opportunities and challenges in cancer.
    Best JD; Carey N
    Drug Discov Today; 2010 Jan; 15(1-2):65-70. PubMed ID: 19897050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Some thoughts on experimental screening.
    Carter SK
    Biomedicine; 1975 Jan; 22(1):5-17. PubMed ID: 1101978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenome: a new target in cancer therapy.
    Giacinti L; Vici P; Lopez M
    Clin Ter; 2008; 159(5):347-60. PubMed ID: 18998037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rational drug design.
    Mandal S; Moudgil M; Mandal SK
    Eur J Pharmacol; 2009 Dec; 625(1-3):90-100. PubMed ID: 19835861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic changes in cancer as potential targets for prophylaxis and maintenance therapy.
    Grønbaek K; Treppendahl M; Asmar F; Guldberg P
    Basic Clin Pharmacol Toxicol; 2008 Nov; 103(5):389-96. PubMed ID: 18947362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemical approaches to the discovery and development of cancer therapies.
    Neidle S; Thurston DE
    Nat Rev Cancer; 2005 Apr; 5(4):285-96. PubMed ID: 15803155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Scaffold/matrix attachment regions (S/MARs): relevance for disease and therapy.
    Gluch A; Vidakovic M; Bode J
    Handb Exp Pharmacol; 2008; (186):67-103. PubMed ID: 18491049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New agents and approaches to the treatment of B-cell non-Hodgkin lymphoma.
    Burton JD; Goldenberg DM
    Expert Opin Emerg Drugs; 2010 Dec; 15(4):569-83. PubMed ID: 20828225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The development of molecularly targeted anticancer therapies: an Eli Lilly and Company perspective.
    Perry WL; Weitzman A
    Clin Adv Hematol Oncol; 2005 Mar; 3(3):199-202, 237-8. PubMed ID: 16166991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rational combinations using HDAC inhibitors.
    Bots M; Johnstone RW
    Clin Cancer Res; 2009 Jun; 15(12):3970-7. PubMed ID: 19509171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The contemporary drug development process: advances and challenges in preclinical and clinical development.
    Garrett MD; Walton MI; McDonald E; Judson I; Workman P
    Prog Cell Cycle Res; 2003; 5():145-58. PubMed ID: 14593708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic deregulation of DNA repair and its potential for therapy.
    Hegi ME; Sciuscio D; Murat A; Levivier M; Stupp R
    Clin Cancer Res; 2009 Aug; 15(16):5026-31. PubMed ID: 19671858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving the evaluation of new cancer treatments: challenges and opportunities.
    Rothenberg ML; Carbone DP; Johnson DH
    Nat Rev Cancer; 2003 Apr; 3(4):303-9. PubMed ID: 12671669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prodrug strategies in anticancer chemotherapy.
    Kratz F; Müller IA; Ryppa C; Warnecke A
    ChemMedChem; 2008 Jan; 3(1):20-53. PubMed ID: 17963208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel approaches on epigenetics.
    Papait R; Monti E; Bonapace IM
    Curr Opin Drug Discov Devel; 2009 Mar; 12(2):264-75. PubMed ID: 19333872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Target selectivity of anticancer drugs].
    Fattoruso SI; Di Lauro L; Conti F; Amodio A; Lopez M
    Clin Ter; 2008; 159(3):189-206. PubMed ID: 18594750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies for optimizing combinations of molecularly targeted anticancer agents.
    Dancey JE; Chen HX
    Nat Rev Drug Discov; 2006 Aug; 5(8):649-59. PubMed ID: 16883303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delivery of epidrugs.
    el Bahhaj F; Dekker FJ; Martinet N; Bertrand P
    Drug Discov Today; 2014 Sep; 19(9):1337-52. PubMed ID: 24680930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-mammalian models for epigenetic analyses in cancer.
    Schaefer M; Meusburger M; Lyko F
    Hum Mol Genet; 2007 Apr; 16 Spec No 1():R1-6. PubMed ID: 17613542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.